ImmunityBio, Inc 10-Q for FY2026 Q1
ImmunityBio, Inc. (IBRX)
10-Q
2026-05-07
For: 2026-03-31
View Original
Added on
May 07, 2026
About this 10-Q
ImmunityBio, Inc filed this 10-Q on May 7, 2026, covering the quarter ended March 31, 2026 (FY2026 Q1).
Headline figures
Quarter ended March 31, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $44.21M
- up 167.6% from $16.52M a year earlier
- Net loss
- $632.78M
- compared with a net loss of $129.65M a year earlier
- Diluted EPS
- -$0.62
- compared with -$0.15 a year earlier